GlobeNewswire: VIVUS, Inc. Contains the last 10 of 179 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T11:59:54ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/01/08/2805507/0/en/VIVUS-Provides-Update-on-Pipeline-and-Program-Milestones.html?f=22&fvtc=4&fvtv=14282VIVUS Provides Update on Pipeline and Program Milestones2024-01-08T14:00:00Z<![CDATA[CAMPBELL, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, today announced pipeline updates and program milestones.]]>https://www.globenewswire.com/news-release/2023/11/28/2787056/0/en/New-Clinical-Data-Demonstrate-that-QSYMIA-the-Leading-Once-Daily-Oral-Weight-Management-Medication-Reduces-Blood-Pressure.html?f=22&fvtc=4&fvtv=14282New Clinical Data Demonstrate that QSYMIA®, the Leading Once-Daily Oral Weight-Management Medication, Reduces Blood Pressure2023-11-28T14:00:00Z<![CDATA[CAMPBELL, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, today announced positive topline data from a post-marketing study to evaluate the effect of QSYMIA® (phentermine and topiramate extended-release capsules CIV) on 24-hour ambulatory blood pressure (ABPM) (#NCT05215418). This study, which enrolled patients with overweight or obesity who also had at least one weight-related comorbidity (i.e., hypertension, dyslipidemia, impaired fasting glucose or glucose tolerance, type 2 diabetes mellitus, or obstructive sleep apnea) demonstrated that QSYMIA treatment for eight weeks was associated with reductions in systolic blood pressure as assessed by ABPM compared to both placebo and phentermine. Obesity and high blood pressure are significant risk factors for the development of cardiovascular disease.]]>https://www.globenewswire.com/news-release/2023/05/17/2670696/0/en/VIVUS-QSIVA-in-Combination-with-a-Digital-Lifestyle-Intervention-Leads-to-Significant-Weight-Loss-and-Decreased-Cardiovascular-Risk-in-Patients-with-Obesity.html?f=22&fvtc=4&fvtv=14282VIVUS’ QSIVA in Combination with a Digital Lifestyle Intervention Leads to Significant Weight Loss and Decreased Cardiovascular Risk in Patients with Obesity2023-05-17T07:30:57Z<![CDATA[— Poster presented at the 30th European Congress on Obesity (ECO 2023) shows addition of QSIVA provides benefits compared with Digital Lifestyle Intervention (DLI) alone in improving health outcomes in adults with obesity —]]>https://www.globenewswire.com/news-release/2023/01/10/2586253/0/en/VIVUS-Announces-Key-Management-Updates-to-Support-Global-Expansion-Strategy.html?f=22&fvtc=4&fvtv=14282VIVUS Announces Key Management Updates to Support Global Expansion Strategy2023-01-10T14:00:00Z<![CDATA[CAMPBELL, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- VIVUS LLC today announced the promotion of Santosh T. Varghese, MD, to President VIVUS Global Pharmaceutical Development. With more than 25 years of U.S. and global pharmaceutical industry experience, including more than a decade at VIVUS, Dr. Varghese will continue to serve as the company’s Chief Medical Officer.]]>https://www.globenewswire.com/news-release/2022/07/20/2482773/0/en/FDA-Approves-QSYMIA-for-the-Treatment-of-Obesity-in-Adolescents-Ages-12-17.html?f=22&fvtc=4&fvtv=14282FDA Approves QSYMIA® for the Treatment of Obesity in Adolescents Ages 12-172022-07-20T13:00:00Z<![CDATA[CAMPBELL, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- VIVUS LLC today announced that the U.S. Food and Drug Administration (FDA) approved QSYMIA (phentermine and topiramate extended-release capsules) CIV for use in the treatment of obesity in adolescents (12-17 years old) with an initial body-mass index (BMI) in the 95th percentile or greater standardized for age and sex. According to the CDC, approximately 22% of children aged 12-19 years in the United States — about 14 million individuals — have obesity.]]>https://www.globenewswire.com/news-release/2020/12/11/2144066/0/en/VIVUS-Receives-Court-Approval-of-Joint-Chapter-11-Plan-of-Reorganization.html?f=22&fvtc=4&fvtv=14282VIVUS Receives Court Approval of Joint Chapter 11 Plan of Reorganization2020-12-11T21:50:27Z<![CDATA[CAMPBELL, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (the “Company”), a biopharmaceutical company, today announced that it has received approval from the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) on its Second Amended Joint Prepackaged Chapter 11 Plan of Reorganization of VIVUS, Inc. and Its Affiliated Debtors [Docket No. 339] (the “Plan”).]]>https://www.globenewswire.com/news-release/2020/11/14/2126807/0/en/VIVUS-Seeks-Bankruptcy-Court-Approval-of-Second-Amended-Joint-Chapter-11-Plan-of-Reorganization-and-Existing-Stock-Record-Date.html?f=22&fvtc=4&fvtv=14282VIVUS Seeks Bankruptcy Court Approval of Second Amended Joint Chapter 11 Plan of Reorganization and Existing Stock Record Date2020-11-14T01:30:00Z<![CDATA[CAMPBELL, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- On November 10, 2020, VIVUS, Inc. (the “Company”), a biopharmaceutical company, filed the Second Amended Joint Prepackaged Chapter 11 Plan of Reorganization of VIVUS, Inc. and Its Affiliated Debtors [Docket No. 339] (as may be amended, modified, or supplemented from time to time, the “Plan”) with the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”). As set forth in a letter filed with the Bankruptcy Court (the “Equity Support Letter”), the Plan has the full support of the official committee of equity security holders appointed in the Company’s chapter 11 case (the “Equity Committee”) and incorporates the terms and conditions of the plan support agreement filed with the Bankruptcy Court on November 5, 2020 [Docket No. 329] and available, along with all other documents filed with the Bankruptcy Court, on the electronic case filing docket and free of charge on the website maintained by the Company’s voting agent, Bankruptcy Management Solutions, Inc. d/b/a Stretto (the “Voting Agent”) at https://cases.stretto.com/vivus/. This press release is qualified in its entirety by the Plan and the Plan Supplement (as defined herein), which govern in the event of any inconsistency. Unless otherwise indicated, all capitalized terms used herein have the same meaning assigned in the Plan.]]>https://www.globenewswire.com/news-release/2020/07/07/2058956/0/en/VIVUS-Completes-Solicitation-for-In-Court-Reorganization-Plan-to-Become-a-Wholly-Owned-Subsidiary-of-IEH-Biopharma-LLC.html?f=22&fvtc=4&fvtv=14282VIVUS Completes Solicitation for In-Court Reorganization Plan to Become a Wholly Owned Subsidiary of IEH Biopharma LLC2020-07-07T20:49:46Z<![CDATA[CAMPBELL, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has completed the solicitation of an in-court prepackaged plan of reorganization, under which IEH Biopharma LLC (“IEH”) will take 100% ownership of VIVUS (the “Prepackaged Plan”), ahead of its July 7, 2020 chapter 11 filing. The Company solicited IEH―as the only holder of claims in classes entitled to vote on the Prepackaged Plan―and has received IEH’s ballots voting in favor of the Prepackaged Plan in accordance with the amended and restated Restructuring Support Agreement executed by the Company and IEH on July 6, 2020. The Company believes that the Prepackaged Plan satisfies all requirements necessary for confirmation by the Court. The Company will request a combined disclosure statement and confirmation hearing for August 17, 2020, subject to the Court’s availability. Upon confirmation of the Prepackaged Plan, the Company intends to consummate the restructuring transactions shortly thereafter.]]>https://www.globenewswire.com/news-release/2020/06/02/2042123/0/en/VIVUS-Announces-Updated-Agreement-with-Icahn-Enterprises-Holdings-L-P.html?f=22&fvtc=4&fvtv=14282VIVUS Announces Updated Agreement with Icahn Enterprises Holdings L.P.2020-06-02T11:30:00Z<![CDATA[CAMPBELL, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has updated its agreement regarding its corporate debt with Icahn Enterprises Holdings L.P. (dba IEH Biopharma LLC), which holds a principal amount of approximately $170.2 million of the Company’s Convertible Senior Notes.]]>https://www.globenewswire.com/news-release/2020/05/06/2028819/0/en/VIVUS-Reports-First-Quarter-2020-Financial-Results.html?f=22&fvtc=4&fvtv=14282VIVUS Reports First Quarter 2020 Financial Results2020-05-06T20:05:00Z<![CDATA[Company to host conference call today at 4:30pm ET]]>